Merovingian...Like I said, it was sent to investors of a hedge fund with a micro-cap component. I'm guessing it was written by the research department at the hedge fund, or the fund licensed the research from a third party. Since it is dated February 28th, which was preceded by a couple high volume up days, I'm thinking the fund took a position and then issued the report to clients. Don't get too excited, though, just because a hedge fund took a position. This stock's future rests on a sweet licensing deal with big pharma and a hedge fund buying in doesn't relate to that at all.
DISCLAIMER: NEVER ASSUME INFO ON MESSAGE BOARDS TO BE ACCURATE. ALWAYS DO YOUR OWN DUE DILIGENCE. DON'T BUY STOCK BASED ON THIS POST OR ANY OTHER POST. I OWN A LONG POSITION IN THIS STOCK AND THEREFORE I AM BIASED.